Dostmann CV 1 Curriculum Vitae Wolfgang R. Dostmann University

Transcription

Dostmann
CV
Curriculum Vitae
Wolfgang R. Dostmann
University of Vermont
College of Medicine
Department of Pharmacology
Burlington, Vermont 05405, USA
vox: (802) 656-0381
fax: (802) 656-4523
e-mail: [email protected]
web: http://www.uvm.edu/~wdostman
I. Personal Data
Birthdate:
Birthplace:
Marriage:
Citizenship:
Home Address:
52 Collamer Court
Shelburne, VT 05482
vox: (802) 985-2173
December 30, 1956
Bremen, Germany
Evelyn Lüttin, 1987
Germany; US permanent residency
II. Education
● November 13, 1996
Dr. med. habil. (Habilitation)
Institute of Pharmacology & Toxicology, Technical University of Munich, Germany.
Director: Prof. Dr. Franz Hofmann
Thesis: The structures of cAMP- and cGMP-dependent protein kinases
● June 18, 1987
Dr. rer. nat. (Ph.D.)
Institute of Organic Chemistry, University of Bremen, Germany.
Advisor: Prof. Dr. Bernd Jastorff
Thesis: Adenosine-3',5'-cyclic-phosphorothioate (cAMPS): Methods for the synthesis and
biological properties of new types of cAMP analogs
● June 16, 1983
Dipl. Chem. (M.S.)
Institute of Organic Chemistry, University of Bremen, Germany.
Thesis: Synthesis of selected 5'-amino-nucleosides and nucleotides of adenosine
● Oct. 1976 - Oct. 1983
University of Bremen, Germany. Department of Chemistry.
1976-1979: General Chemistry.
1979-1983: Major in Organic Chemistry.
● May 1976
Abitur, Gymnasium 'Kurt-Schumacher-Allee', Bremen, Germany
1
Dostmann
●
●
●
●
●
●
●
●
●
●
CV
III. Academic Appointments
July 2009 – present
Professor (tenure)
Department of Pharmacology, University of Vermont, College of Medicine, Burlington,
Vermont, USA
Adjunct Appointment: Department of Molecular Physiology & Biophysics
July 2004 – June 2009
Associate Professor (tenure)
Department of Pharmacology, University of Vermont, College of Medicine, Burlington,
Vermont, USA
Adjunct Appointment: Department of Molecular Physiology & Biophysics
March 1998 -June 2004
Assistant Professor, Department of Pharmacology, University of Vermont, College of Medicine,
Burlington, Vermont, USA
Joint Appointment: Department of Molecular Physiology & Biophysics
April 1997 - April 1998
Privatdozent (Senior Lecturer)
Institute of Pharmacology and Toxicology, Faculty of Medicine, Technical University of Munich,
Germany.
Feb. 1991 - March 1997
Assistant (Lecturer)
Institute of Pharmacology and Toxicology, Technical University of Munich, Germany. Director:
Prof. Dr. Franz Hofmann
May 1991 - Aug. 1991
Visiting Scholar
University of Bergen, Center for Molecular Medicine, Bergen, Norway
Host: Prof. Dr. Dagfinn Øgreid
April 1989 - Jan. 1991
Research Associate
University of California at San Diego, California, USA.
Mentor: Prof. Dr. Susan S. Taylor
Nov. 1987 - March 1989
Post-Doctoral Fellow
University of California at San Diego, California, USA.
Mentor: Prof. Dr. Susan S. Taylor
Feb. 1985 - July 1985
Visiting Scholar
Sandoz Research Institute, Sandoz Inc., East Hanover, New Jersey, USA
Host: Dr. Lynne Botelho-Parker
Feb. 1983 - July 1987
Graduate Student and Teaching Assistant
University of Bremen, Institute of Organic Chemistry, Bremen, Germany
2
Dostmann
●
●
●
●
●
IV. Awards & Honors
Masters Graduation with honors, magna cum laude, Bremen, Germany
Research Award, Sandoz Inc., East Hanover, New Jersey, USA
Doctor Graduation with honors, summa cum laude, Bremen, Germany
Venia legendi, (Privatdozent), Munich/Bavaria, Germany
Lead-User Award (Surface Plasmon Resonance), BioTul Inc, Munich, Germany
V. Fellowships
● Predoctoral Teaching Fellowship, University of Bremen, Germany
● Postdoctoral Fellowship, (Do329/1-1) Deutsche Forschungsgemeinschaft
(DFG), Germany
● Research Fellowship, Norwegian Research Council, University of Bergen,
Norway
VI. Professional Organizations & Societies
● American Association for the Advancement of Science
● Deutsche Gesellschaft für experimentelle und kliniosche Pharmakologie
und Toxikologie
● Gesellschaft für Biochemie und Molekularbiologie
● Deutscher Hochschulverband
● Biophysical Society
● New England Smooth Muscle Society
● American Chemical Society
●
●
●
●
●
VII. Research Funding
Previous Grant Support, Europe
Research Grant, Do329/2-1
Deutsche Forschungsgemeinschaft (DFG), Germany
Title: Protein Kinases
Role: PI
Role: PI
Research Grant, CRG 941235
NATO, Brusselles, Belgium
Title: cAMP- and cGMP-dependent protein kinases
Role: PI
Role: PI
CV
1983
1985
1987
1997
1998
1983 - 1987
1987 - 1989
1991
1989 1992 - 2001
1994 - 2001
1996 1998 1999 2002 -
1991 - 1993
1993 - 1995
1994 - 1997
1995 - 1997
1996 - 1998
3
Dostmann
CV
Title: Allosteric Enzymes
Role: PI
●
●
●
●
●
●
●
●
●
Previous Grant Support, USA
Start-up funds
1998 - 2001
Department of Pharmacology, Department of Physiology & Molecular
Biophysics, Vermont Cancer Center
Research Grant
1999 - 2000
UVM, Research Advisory Council
Title: Development of real time protein-ligand binding assays by the use of
Surface-Plasmon Resonance (SPR), $22,000 (direct)
Role: PI
New Investigator Research Initiative
1999 - 2000
UVM, College of Medicine
Title: cGMP and cGMP-dependent protein kinases: their roles in intracellular
signaling. $7,500 (direct)
Role: PI
Research Grant
1999 - 2000
Lake Champlain Cancer Research Organization (LCCRO)
Title: The Role of Cyclic Nucleotides in Cell Proliferation, $10,000 (direct)
Role: PI
Research Grant, 9920260T
1999 - 2001
American Heart Association
Title: Design of in vivo indicators of cGMP, $60,000 (direct)
Role: PI
Research Grant, MCB-9983097
2000 - 2004
National Science Foundation (NSF)
Title: Design of in vivo indicators for cyclic-GMP, $360,191 (indirect)
Role: PI
Research Grant
2000 - 2002
Department of Energy, DOE-EPSCoR Structural Biology Cluster,
Title: Structural characterization of cGMP-dependent protein kinase Iα and
it’s complexes with high affinity inhibitors, $90,000 (direct)
Role: Co-Investigator
Research Grant
2001 - 2002
Lake Champlain Cancer Research Organization (LCCRO)
Title: Protein Transduction: Membrane translocation signals and their
possible roles in cancer therapy, $10,000 (direct)
Role: PI
Research Grant, RO1 HL68991-01
2002 - 2006
National Institute of Health, NIH/NHLBI
Title: Exploring vasomotor mechanism using new PKG inhibitors,
$1,488,750 (indirect)
Role: PI
4
Dostmann
CV
● Research Grant, Cardiovascular Disease Division
2003 - 2005
Aventis Pharma, Germany
Title: Genetically encoded, in vivo cGMP-indicators: screening of intracellular
cGMP transients in single live cells, evoked by novel soluble guanylyl cyclase activators,
$53,000 (direct)
Role: PI
● Large Equipment Grant, 1S10RR19246-01
2004
National Institute of Health (NIH)
Title: Inverted Laser-Scanning Confocal Microscope, $550,000
Role: Co-PI
Active Grant Support
● Research Grant
4/15/2006 – 10/31/2011
BayerHealthcare, Germany
Title: Characterization of PKG Activators and Crystallization of PKG and Co-Crystallisation with
PKG Activators. $50,000 (direct)
Role: PI
● Research Grant
5/15/2007 – 10/31/2009
BayerHealthcare, Germany
Title: Analyzing the redox equilibrium of soluble guanylyl cyclase in vascular smooth muscle
using BAY 58-2667 and cGMP biosensors, $37,000 (direct)
Role: PI
● Research Grant, R01 HL68991-02
4/01/2008 – 3/31/2013
Title: Exploring vasomotor mechanism using new PKG inhibitors and cGMP biosensors.
Direct annual award, $250,000
Role: PI
● Internal Research Grant (IGP),
8/01/2010-7/31/2012
College of Medicine, UVM
Title: The crystal structure of cGMP-dependent protein kinase
● Research Grant, R01 DK56644, PI: Steven Lidofsky
9/21/2001-4/30/2012
National Institute of Health, NIH/NIDDK
Title: Mechanisms of cell volume regulation in liver. Direct annual award, $212,500
● Research Grant, R37 DK053832, PI: Mark T. Nelson
8/1/1098-5/31/2018
National Institute of Health, NIH/NIDDK
Title: Ca2+ sparks and urinary bladder smooth muscle excitability.
Direct annual award, $215,000
● Research Grant, R01 HL085646-01, PI: Albert van der Vliet
08/05/2008-06/30/2012
Title: Dual Oxidase in Airway Epithelial Repair and Remodeling, Direct annual award, $250,000
5
Dostmann
●
●
●
●
●
●
●
●
●
●
●
CV
VIII. Service
Department
Graduate Studies Committee, Department of Molecular Physiology &
1999 - 2002
Biophysics
Medical Library, Journal Review Survey Liaison for the Department of
2002 - 2005
Pharmacology
Department of Pharmacology, Organizer of the Departmental
2002 - 2004
Seminar Series
Physiology and Pharmacology Graduate Program Development Committee
2007
Faculty Search Committees
Department of Pharmacology
1999
Signal Transduction Group/ Vermont Cancer Center
2000
Department of Pharmacology/Vermont Cancer Center
2002-2003
Department of Molecular Physiology & Biophysics
2004
Thesis Committees
Laura Cartin, Department of Pharmacology. Defense: December 16, 1999
Brian Nibbelink, Department of Physiology. Defense: January 9, 2002
Norman Hughes, Department of Chemistry, chair, Defense: March 1, 2002,
Delmy Diaz, Department of Chemistry, chair. Defense: August 12, 2003
Chris Okwuchukwuasanya, Department of Pharmacology/Physiology, advisor.
Defense: August 29, 2003
Renee Pulver, Department of Pharmacology, Defense: January 21, 2005
Carolyn Sawyer, Department of Pharmacology, advisor, Defense: May 13, 2005
Peter Bove, Department of Pathology, chair, Defense, December 2006
Sharon Cawley, Cell & Molecular Biology Program, advisor, Defense, March 5, 2007
Jayanthi Garudathri, Department of Microbiology and Molecular Genetics, chair
Defense, October 30, 2007
Lydia Nausch, Department of Pharmacology, advisor,
Defense, December 5, 2007
Kara Brunelle, Cell & Molecular Biology Program, advisor, Defense, March 26, 2010
Shiv Kumar Raidas, Cell & Molecular Biology Program, advisor, Defense, January 5, 2009
Brent Osborne, Cell & Molecular Biology Program, advisor
Andrew Menke, Cell & Molecular Biology Program, advisor
College
Vermont Cancer Center (VCC), Program Leader, Signal Transduction
Focus Group
College of Medicine Graduate and Medical Student Research Forum
Committee
College of Medicine Research Committee,
chair since June 2003
College of Medicine LCME Committee
Cell & Molecular Biology Program (CMB) Education Committee
1998 - 2000
2000 -2002
2001 2004 - 2005
2005 - 2009
6
Dostmann
CV
University
● University of Vermont Radiation Safety Committee
● Faculty Senate Professional Standards Committee
2007 2008 -
IX. External Service
National Study Section and Review Committees
● National Science Foundation (NSF)
2001
Molecular and Cellular Bioscience Study Section
● National Institute of Health,
2003
Molecular, Cellular and Developmental Neurosciences, MCDN-4 Study Section
● American Heart Association
2004 - 2007
Molecular Signaling, Immunology & Microbiology, North East Affiliate,
NEA 4 Study Section
External Advisory Committees
● Brownfields Advisory Committee
10/09/2007 - 12/19/2007
Agency of Natural Resources and the Agency of Commerce and Community Development, State
Government of Vermont, Montpellier, VT
The Brownfields Advisory Committee had been created as an advisory committee to the
governor to develop proposed statutory and programmatic recommendations that promote the
redevelopment of contaminated properties and address issues identified by developers of
these properties.
I served as a "public health expert on issues related to the protection of people with sensitivity
to certain forms of contamination".
The final report, ‘Report to the Vermont Legislature by the Brownfields Advisory Committee
Established by Act No. 67 of the 2007-2008 Legislative Session’ was issued December 19, 2007
and submitted to the Senate Committee on Economic Development, Housing and General
Affairs, the Senate Committee on Natural Resources and Energy, and the House Committee on
Natural Resources and Energy.
●
●
●
●
Public Outreach Activities
Vermont Public Television
‘Vital Signs’ – Toxins in our Homes (interview and report on Carbon Monoxide Poisoning,
including my research at UVM)
First aired Jan. 4, 2006
WOKO Radio
Interview, Carbon Monoxide Poisoning
First aired Jan. 15, 2006
ClearChannel Radio
Interview, The threat from Corbon Monoxide
First aired Feb. 11, 2006
WCAX- Channel 3 Television
‘Across the Fence’ - Toxins in our homes
First aired April 25
7
Dostmann
CV
● WCAX-Channel 3 News Live
Toxins in our homes
Evening News Live, April 24, 2006
● Community Medical College, University of Vermont and Vermont Public Television Toxins in our
Homes,
April 25, 2006 (aired throughout 2006 at VPT)
● WCAX- Channel 3 Television
Toxicity of lead paint, Interview
Evening News, aired May 2, 2006
● The Burlington Free Press
Understanding household toxins can save lives
Health & Healing, May 16, 2006
External Thesis Committees
● Markus Moosmeier, Department of Pharmacology, University of Vermont / Fachhochshule
Weihenstephan, Germany, advisor
Defense: August 4, 2003
● Arjen Scholten, Department of Pharmacology, University of Vermont / University of Utrecht,
The Netherlands, advisor
Defense: October 16, 2006
Journal reviews
Biochemistry
Mol Pharm
Nature
J Biol Chem
Circ Res
Prot Sci
J Clin Invest
Chem Res Tox
J Cell Signal
Brit J Pharm
J Vasc Pharm
Proc Natl Acad Sci USA
Am J Physiol
Science
EMBO J
Current Biol
Chem & Biol
Structure
Eur J Pharm
Biophys Biochem Acta
Circulation
X. Trainees - Technical University of Munich (1991 - 1998)
Graduate Students
● Robert Endres, Dr. med. (M.D), July 1991 - May 1993, Thesis: Subcloning, bacterial expression
and characterization of the catalytic and regulatory domains of cGMP-dependent protein kinase
I. Current position: Group Leader, Institute of Medical Microbiology, Technical University of
Munich, Germany
● Norbert Wild, Dr. rer. nat. (Ph.D), November 1992 - August 1995. Thesis: Construction of cGMPsensitive, regulatory subunits of cAMP-dependent protein kinase. Current position: Group
Leader, Roche Diagnostics GmbH, Penzberg, Germany
8
Dostmann
CV
● Michaela Zorn, Dr. rer. nat. (Ph.D), (B. Jastorff co-advisor, University of Bremen), February 1994
– November 1995, Thesis: Structure-function relationship of cAMP on molecular and cellular
levels. Current position: Post-doc, Institute of Experimental Physics, University of Bremen,
Germany
● Kurt Pawlitschko, Dipl. Biol. (M.S), October 1994 - December 1995. Thesis: Identification of
essential amino acid residues for the activation of PKG I. Current position: Staff Scientist,
BioRad, Munich, Germany
● Angelika Gillitzer, Dipl. Biol. (M.S), September 1995 - February 1998, Thesis: Ligand selectivity of
recombinant mutants of the cGMP-dependent protein kinase. Current position: Staff Scientist,
ProCorde GmbH, Martinsried (Munich), Germany
●
●
●
●
●
●
●
●
●
Technicians
Nicole Koep, BTA, Biology School Cologne, September 1991 - February 1994.
Elke Pross, CTA, Chemistry School Munich, January 1994 - July 1994.
Iris Kühnert, PTA, Pharmaceutical School Munich, August 1994 - March 1996
Stefan Thiel, CTA, Chemistry School Frankfurt, December 1996 - February 1998
Christian Nickl, CTA, Chemistry School Munich, Technician March 1997 - April 1998
XI. Trainees - University of Vermont (1998 - present)
Postdocs
Akira Honda, Ph.D., University of Tokyo, June 1998 – August 2004, Project: Wavelength
mutations of GFP and their use as FRET indicators. Current position: Associate Professor,
Kyushu University, Fukuoka, Japan
Kevin F. Foley, Ph.D., Eastern Carolina School Of Medicine, April 2002 – September 2003.
Project: Kinetic analysis of membrane translocation signal peptides. Current position: Assistant
Professor, Northern Michigan University
Sergio De Frutos Garcia, Ph.D. University of Madrid, Spain, April 2004 – April 2005. Project: The
role of PKG in smooth muscle phenotype modulation. Current position: Assistant Professor,
University of New Mexico, Albuquerque, NM
Kara F Held, Ph.D, University of Vermont, April 2010-August 2010, Kinetic Modeling of NO and
cGMP. Current Position: Post-doc, Yale University, CT
Graduate Students
● Carolyn Sawyer, Ph.D., November 1998 – January 2004, Thesis: Development of fluorescent
cGMP-indicators and their use to study the spatial and temporal dynamics of cGMP in vascular
smooth muscle cells. Current position: Associate Director of Scientific Communications,
Novartis, Boston, MA
● Chris Okwuchukwuasanya, M.S., October 2000 - August 2003, Thesis: Characterization of a
novel cGMP-dependent protein kinase G inhibitor and its effect on basal kinase activity in rat
cerebral arteries. Current position: Vermont Law School, Burlington, VT
● Markus Moosmeier, M.S., Foreign Graduate Student, Fachhochschule Weihenstephan,
Germany, July 2002 – January 2003, Thesis: Membrane permeable Cygnets: a novel technique
for rapid cellular internalization of fluorescent cGMP-indicators, Current position: Graduate
Student, German Cancer Research Center, Heidelberg, Germany
9
Dostmann
CV
● Arjen Scholten, Ph.D., Foreign Graduate Student, Utrecht University, January 2002 – October
2006, Thesis: Analysis of PKG inhibitor peptides using nano-flow ESI-mass spectrometry, Current
position: Assistant Professor, Utrecht University, The Netherlands
● Sharon M. Cawley, Ph.D., June 2002 – March 2007 , Thesis: Nitric Oxide induced Cyclic GMP
dynamics in Vascular Smooth Muscle Cells using a FRET-based indicator. Current position: Post
doctoral Fellow, Harvard Medical School, MGH, Boston, MA
● Lydia Nausch, Ph.D, July 2004 – December 2007, Thesis: Novel insights into PKG and cGMP
signaling in response to NO and ANP in vascular smooth cells, Current position: Post doctoral
Fellow, Department of Pharmacology, UVM, VT
● Shivkumar Raidas, April 2005 – 2009, Thesis: Novel activators and inhibitors of cGMP-dependent
protein kinase
● Kara Brunelle, April 2005 – 2010. Thesis: The spatial and temporal dynamics of intracellular
cGMP in vascular smooth muscle cells
● Brent Osborne, January 2006 – present, Thesis: Development of cAMP-biosensors
● Andrew Menke, August 2010 – present. Rotation: Mutational analysis of cGMP-biosensors
●
●
●
●
●
●
●
●
●
●
●
●
Undergraduate Trainees
Hendrik Fuss, Biotechnology, Fachhochschule Weihenstephan, Germany, September 1999 –
Feb. 2000, Project: Fluorescence based unfolding experiments on PKG
Timo Sieber, Biotechnology, Fachhochschule Weihenstephan, Germany, July 2000 - February
2001, Project: Solution competition peptide libraries to screen cGMP-dependent protein kinase
inhibitors
Markus Moosmeier, Biotechnology, Fachhochschule Weihenstephan, Germany, March – Sept.
2001. Project: MPP-cygnets: membrane permeable cGMP-indicators
Bridget Shea, University of New Hampshire, June - August 2003, Summer student. Project:
Cygnets - cGMP-indicators in vascular smooth muscle cells
Benedikt Koene, Fachhochschule Weihenstephan, Germany, August 2003- December 2003,
Project: Activators of mammalian soluble guanylyl cyclases
Bridget Shea, University of New Hampshire, June - August 2004, Summer student,
HELiX/EPSCoR fellowship. Project: Using cGMP-indicators to study the dynamics of intracellular
cGMP in single living vascular smooth muscle cells.
Bernd Zetsche, College of Higher Education Gelsenkirchen, Faculty of Applied Sciences,
Germany, February 2005 - August 2005, Project: HMR-1766 mediated cGMP responses in
vascular smooth muscle cells
Caitlin McFarland, Roberts Wesleyan College, Rochester, NY. May - August 2008, Project: The
dynamics of cGMP in pulmonary smooth muscle cells
Arben Koitera, University of Vermont, Biology, September 2008 – present. Project: Mutational
analysis of cGMP-biosensors
Andrew Ohl, University of Vermont, Biology, September 2008 – present. Project: Crystallization
of the regulatory domain of cGMP-dependent protein kinase.
Ann-Marie Mc Kenna, Queens University, Biomedical Science, Belfast, N. Ireland. September
2008 – July 2009. Project: Fruity-FlincGs: Wavelength mutations of cGMP-biosensors
Meagan Anne Quinlan, University of Vermont, Psychology, May 2010 – present, Project:
Expression and purification of PKG mutant enzymes
10
Dostmann
CV
● Nicole Maille, University of Vermont, Biochemistry, September 2010 – present, Project: Binding
site mutants of cGMP-dependent protein kinase
●
●
●
●
●
●
●
●
●
●
●
Technicians
Cheryl C. Collins, M.S., University of Vermont, Technician level IV, April 1998 - March 1999
Christian Nickl, CTA, Chemistry School Munich, Germany, Technician level I/II/III, April 1998 –
present.
Kristina Laskovski, B.S., Mt. Holyoke College, Technician III, September 2003 – August 2005
Caitlin McFarland, Roberts Wesleyan College, Rochester, NY. June 2009 -, Project: The dynamics
of cGMP in smooth muscle cells
XII. Teaching
University of Bremen (1983 - 1987)
Seminars and Laboratory Courses for Students of Chemistry (Teaching Assistant):
Inorganic Chemistry I
Organic Chemistry I
Organic Chemistry II
Organic Chemistry III
Chromatography
Bio-Organic Chemistry
Seminars and Laboratory Courses for Students of Biology:
Chemistry for Biology Majors
University of California, San Diego (1987 - 1991)
● Seminar in Molecular Biology: Techniques in Recombinant DNA handling and Site-Directed
Mutagenesis
● Seminar in Biochemistry: Protein- Biochemistry: Expression and Purification of Recombinant
Proteins
Technical University of Munich (1991 - 1998)
Medical School
● General Pharmacology and Toxicology Course for Medical Students, 150 students, Fall & Spring
Semesters, 1993 – 1998
Lecture titles:
Toxicology
Pharmacology of the brain
Pharmacology of the lung
Pharmacology of the heart
Pharmacology of the digestive system
Analgesics
Anti-cancer therapy
● Clinical Pharmacology Course for Medical Students, 150 students, Fall & Spring Semesters,
1995 - 1998
Lecture titles:
11
Dostmann
CV
Anti-neoplastic therapy I
Anti-neoplastic therapy II
● Pharmacology Course plus Laboratory Course for Students of Natural Sciences, 10 students, Fall
Semester, Course Director, 1991 - 1998
Lecture titles:
General Pharmacology
Pharmacokinetics and Phamacodynamics
Second Messenger Signaling
Reversible Phosphorylation
Kinetic Analysis of Receptor-Ligand Interactions
Principles of Toxicology
University of Vermont (1998 - present)
Medical School
● Pharmacology 301, 2nd year Medical students, Fall Semester, 100 students, 1998 - 2003,
Average student evaluation: 4.48
● Pharmacology 301a, 2nd year Medical students, Spring Semester, 20 students, 1998 – present,
Average student evaluation: 4.29
● The Vermont Integrated Curriculum, Attacks and Defenses, 1st year Medical students, Spring
Semester, 100 students, 2003 – present, Average student evaluation: 3.94
Lecture titles:
Toxicology: Toxic Gases
Toxicology of Heavy Metals
Treatment of Heavy Metal Poisoning
Toxicology of Pesticides and Polychlorinated Hydrocarbons
Environmental Toxicology
Undergraduate/Graduate School Teaching
● PHRM 190 - Pharmacology, Physical Therapy Students (Undergraduate), Spring Semester, 50
students, 1999 – 2001, Average student evaluation: 4.35
Lecture titles:
Anticancer Pharmacology
● PHRM 201 - Introductory Pharmacology, Undergraduate/Graduate Course, Fall Semester, 20
students, 2006 – present, Average student evaluation: 3.94
Lecture titles:
General Pharmacology: Drug - Receptor Interactions
General Pharmacology: Pharmacodynamics
General Pharmacology: Pharmacokinetics
● PHRM 272 - Toxicology, Undergraduate/Graduate Course, Spring Semester, 30 students, 2000 present, Course Director since 2004, Average student evaluation: 4.58
Lecture titles:
History of Toxicology
Carbon monoxide poisoning
12
Dostmann
CV
Cyanide poisoning
Toxicology of Cadmium
Toxicology of Lead
Toxicology of Mercury
Toxicology of Arsenic
Management of heavy metal poisoning
Chemical Warfare
Bioterrorism
Air Pollution: Indoor
Air Pollution: Outdoor
Ecotoxicology I: Environmental Problems, causes, and sustainability
Ecotoxicology II: Environmental Economics
Ecotoxicology III: Ecosystems: Energy Flow and Matter Cycles
Ecotoxicology IV: Ecosystems: The Water Cycle
Ecotoxicology V: The Fate of Pollutants in Ecosystems
Ecotoxicology VI: The Fate of Pollutants in Individuals
Ecotoxicology VII: Environmental Risk Assessment
● PHRM 290, Special topics in Molecular Pharmacology, Graduate Course, Spring Semester,10
students, 1999 – present, Average student evaluation: 4.34
Lecture titles:
Receptor Ligand Interactions
Second Messenger Signaling: cAMP
Second Messenger Signaling: cGMP
● CMB 301, Cell and Molecular Biology Program, Graduate Course, Fall Semester, 20 Students,
2001 – present, Average student evaluation: 4.13
Lecture titles:
Cyclic Nucleotide Signaling
Reversible Phosphorylation
● PHRM 328, Medicinal Chemistry, Graduate Course, Spring Semester,10 students, 2005 –
present, Course Director, Average student evaluation: 4.70
Lecture titles:
History of Drug Discovery
The Most Important Drugs in History
The Pharmaceutical Industry
Drug Discovery, Design and Development
Drug Targets: Intermolecular Forces and Stereochemistry
Drug Targets: Proteins and Enzymes
Drug Targets: Receptors
Drug Targets: Receptor Structure & Signal Transduction
Pharmacokinetics and Pharmacodynamics, Part I
Pharmacokinetics and Pharmacodynamics, Part II
Drug Discovery without a Lead
Drug Discovery: Targeted Screening
13
Dostmann
CV
Drug Discovery: Finding a Lead
Rational Approaches to Lead Discovery: The Pharmacophore
Rational Approaches to Lead Discovery: Isosterism
Drug Design: Strategies in Drug Design
Drug Design: Optimizing Access to the Target
Drug Design: Prodrugs
Analogue- based Drug Discovery
Fragment - based Drug Discovery
Strategies in Drug Optimization
Computer-Aided Drug Design
Structure Activity Relationships
Quantitative Structure Activity Relationships
Antiulcer Drugs – H2 Antagonists
Antiulcer Drugs – Proton Pump Inhibitors
Drugs Affecting the Cardiovascular System: ACE Inhibitors
Drugs Affecting the Cardiovascular System: Calcium Blockers
Drugs Affecting the CNS: Opium Analgesics
Recent Advances in Drug Discovery: Protein Kinase Inhibitors
Recent Advances in Drug Discovery: Antisense Agents
Average student evaluation, all courses: 4.34
●
●
●
●
●
●
●
●
●
●
XIII. Invited Talks and Lectures
1) June 1983
Synthesis of selected 5'-amido-Nucleosides and Nucleotides of
Adenosin, Institute of Organic Chemistry, University of Bremen, Germany
2) April 1985
Alternative methods for the synthesis of cyclic-nucleotides. Diabetes
Research Group, Sandoz Inc., East Hanover, NJ, USA
3) June 1987
Methods for the synthesis of Adenosin-3',5'-cyclothiophosphate (cAMPS),
and selected derivatives: Chemical and biological properties, Institute of Organic Chemistry,
University of Bremen, Germany
4) Nov. 1987
Methods for the synthesis of Adenosin-3',5'-cyclothiophosphate (cAMPS),
and selected derivatives, Department of Chemistry, University of California at San Diego, CA,
USA
5) Nov. 1988
A structural model of the cAMP binding sites of cAMP-dependent
protein kinase, Department of Chemistry, University of California at San Diego, USA
6) Jan. 1989
Mapping of the cAMP-binding sites in cAMP dependent protein kinase by
site directed mutagenesis and cAMP antagonists, Department of Chemistry, University of Utah,
Salt Lake City, UT, USA
7) Sept. 1990
cAMP-Phosphorothioates: Synthesis and applications, Institute of
Anatomy, University of Bergen, Norway
8) October 1990
Struktur der cAMP Bindungsseite der cAMP-Kinase, Medizinische
Biochemie, Universität des Saarlandes, Homburg, Germany
9) July 1991
A structural model of the cGMP-binding sites of cGMP-dependent protein
kinase, Department of Chemistry and Biochemistry, University of California at San Diego, CA
10) January 1992
cAMP- und cGMP-abhängige Proteinkinase: Gemeinsamkeiten und
14
Dostmann
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
CV
Unterschiede in ihrer Struktur, Med. Universitätsklinik, Universität Würzburg, Germany
11) August 1992
cAMP- und cGMP-abhängige Proteinkinase: Strukturelle
Gemeinsamkeiten und Unterschiede, Universität Bremen, Germany
12) Sept. 1993
A structural model of the cGMP-dependent protein kinase. Department of
Chemistry and Biochemistry, University of California at San Diego, USA
13) March 1994
Structural similarities of cAMP- and cGMP-dependent protein kinases,
Institute Pasteur, Paris, France
14) July 1995
Strukturelle Analyse cyclo-Nukleotid-regulierter Proteinkinasen, Med.
Universitätsklinik, Universität Würzburg, Germany
15) July 1995
Strukturelle Analyse cyclo-Nukleotid-regulierter Proteinkinasen,
Gesellschaft für Biotechnologische Forschung (GBF), Braunschweig, Germany
16) July 1995
Strukturelle Analyse cyclo-Nukleotid-regulierter Proteinkinasen,
Universität Bremen, Germany
17) June 1996
Strukturen cAMP und cGMP-abhängiger Proteinkinasen, Institut für
Pharmakologie und Toxikologie, Ludwig-Maximilian-Universität München, Germany
18) Nov. 1996
The structures of cAMP- and cGMP- dependent Protein Kinases, Institute
of Pharmacology and Toxicology, University of Technology Munich, Germany
19) December 1996 Struktur und Funktion cyclo-Nucleotid regulierter Proteinkinasen. Institut
für Pharmakologie, Freie Universität Berlin, Germany
20) May 1997
Struktur und Funktion cyclo-Nucleotid regulierter Proteinkinasen. MaxPlanck-Institut für molekulare Physiologie, Dortmund, Germany
21) June 1997
Struktur und Funktion cyclo-Nucleotid regulierter Proteinkinasen. Institut
für Pharmakologie, Universität Bochum, Germany
22) June 1997
Struktur und Funktion cyclo-Nucleotid regulierter Proteinkinasen. Institut
für Anatomie, Universität Frankfurt, Germany
23) July 1997
New insights in the structure/function relationship of cyclic-nucleotide
dependent protein kinases, Department of Biochemistry, Albert-Einstein-College of Medicine,
Yeshiva University, New York, USA
24) July 1997
The structure/function relationship of cyclic-nucleotide dependent protein
kinases, Department of Pharmacology, College of Medicine, University of Vermont, Burlington,
Vermont, USA
25) Dec. 1997
New insights in the structure/function relationship of cyclic-nucleotide
dependent protein kinases, Department of Medicinal Biochemistry, University of Bergen,
Norway
26) January 1998
Structure/function relationship of cyclic-nucleotide dependent protein
kinases, Glaxo-Wellcome, Department of Endocrinology, Durham, North Carolina, USA
27) June 1998
Structure/function relationship of cyclic-nucleotide dependent protein
kinases, Department of Pharmacology, University of Vermont, VT, USA
28) January 1999
cGMP and cGMP-dependent protein kinase, Department of Biology,
University of Vermont, Burlington
29) April 1999
cGMP and cGMP-dependent protein kinase: the enzyme and its allosteric
regulator in search of an identity, Department of Physiology & Biophysics, University of
Vermont, Burlington, VT
15
Dostmann
CV
● 30) August 1999
cGMP-dependent protein kinase in intracellular signaling, Department of
Chemistry and Biochemistry, University of California at San Diego, CA, USA
● 31) January 2000
Structure - Function Studies on cGMP-dependent Protein Kinase, Cell
Signaling Group, University of Vermont, Burlington
● 32) February 2000 Nitric Oxide and cyclic GMP signaling mechanisms, Department of
Pathology, University of Alabama, Birmingham
● 33) April 2000
The role of cGMP-dependent kinase in the control of vascular smooth
muscle tone, Department of Pharmacology, University of Hamburg, Germany
● 34) April 2000
The role of cGMP-dependent protein kinase in intracellular signaling,
Department of Physiol. Chemistry, University of Bochum, Germany
● 35) October 2000
New aspects in the biochemistry of NO/cGMP signaling: fluorescent
cGMP-indicators and selective inhibitors of cGMP-kinase, Department of Biochemistry, Erasmus
University, Rotterdam, Netherlands
● 36) October 2000
New aspects in the biochemistry of NO/cGMP signaling, Department of
Physiol. Chemistry, University of Bochum, Germany
● 37) Nov. 2000
New aspects in the biochemistry of NO/cGMP signaling: fluorescent
cGMP-indicators and selective inhibitors of cGMP-kinase, Department of Neurobiology,
University of Puerto Rico, San Juan, Puerto Rico
● 38) December 2000 The biochemistry of NO/cGMP signaling: fluorescent cGMP-indicators and
selective inhibitors of cGMP-kinase, Department of Pharmacology, University of Texas Medical
Branch, Galveston, TX
● 39) February 2001 The biochemistry of NO/cGMP signaling, Department of Physiology &
Biophysics, University of Vermont, Burlington, VT
● 40) October 2001
Spatiotemporal dynamics of cGMP revealed by a genetically encoded
fluorescent indicator, Vermont Cancer Center, University of Vermont, Burlington
● 41) Dec. 2001
Exploring the roles of cGMP and cGMP-dependent protein kinase in
intracellular signaling, Department of Biochemistry, University of Vermont, Burlington, VT
● 42) Dec. 2001
fluorescent indicator, Departments of Anatomy and Neurobiology, University of Vermont,
Burlington, VT
● 43) January 2002
Novel developments in cGMP and cGMP-dependent protein kinase
signaling, Department of Chemistry and Biochemistry, University of California at San Diego
● 44) January 2002
Cygnets: spatiotemporal dynamics of intracellular cGMP revealed by
genetically encoded, fluorescent indicators. University of Utrecht, Utrecht Institute for
Pharmaceutical Sciences, Utrecht, The Netherlands
● 45) January 2002
Exploring vasomotor mechanisms using highly selective inhibitors of
cGMP-dependent protein kinase. University of Utrecht, Utrecht Institute for Pharmaceutical
Sciences, Mass Spectrometry Unit, Utrecht, The Netherlands
● 46) February 2002 Exploring the roles of cGMP and cGMP-dependent protein kinase in
intracellular signaling. Department of Biochemistry, University of Vermont, Burlington
● 47) June 2002
intracellular signaling, Department of Pharmacology, Universität Tübingen, Germany
● 48) June 2002
intracellular signaling, Department of Biology, Universität Konstanz, Germany
16
Dostmann
CV
● 49) August 2002
intracellular signaling, Aventis Pharma, DG Cardiovascular Diseases, Frankfurt, Germany
● 50) August 2002
Cygnets: the dynamics of intracellular cGMP revealed by
geneticallyencoded fluorescent indicators. German Research Center for Biotechnology, AG
Molecular Recognition, Braunschweig, Germany
● 51) Sept. 2002
Exploring the Roles of cGMP-dependent Protein Kinase in Intracellular
Signaling, Department of Pharmacology, University of Vermont, Burlington, VT
● 52) February 2003 Exploring the Roles of cGMP-dependent Protein Kinase in Intracellular
Signaling Department of Physiology, University of Nevada, Reno, Nevada
● 53) March 2003
Exploring the Roles of cGMP and cGMP-dependent Protein Kinase in
Intracellular Signaling Department of Biochemistry, University of Glasgow, Scotland
● 54) March 2003
Intracellular Signaling. Université Paris-Sud, Faculté de Pharmacie, Paris, France
● 55) April 2003
Biosynthetic biosensors probe "real time" changes in the kinetics of
intracellular signaling pathways, MD/PhD seminar series, College of Medicine, University of
● 56) April 2003
Intracellular Signaling Department of Physiology, University of South Alabama, Mobile, AL
● 57) May 2003
Intracellular Signaling Department of Microbiology and Molecular Genetics, University of
● 58) May 2003
Intracellular Signaling Department of Pharmacology, Queen’s University, Kingston, Ontario,
Canada
● 59) October 2003
Intracellular Signaling Department of Biochemistry, Molecular Biology and Biophysics University
of Minnesota, Minneapolis, Minnesota
● 60) Nov. 2003
cGMP mediated signaling Departments of Pharmacology and Physiology,
University of Washington, Seattle, Washington
● 61) February 2004 Novel activators of soluble guanylyl cyclase and intracellular cGMP
Aventis Pharma, DG Cardiovascular Diseases, Frankfurt, Germany
● 62) Sept. 2004
cGMP mediated signaling in smooth muscle, German Research Center for
Biotechnology, AG Molecular Recognition, Braunschweig, Germany
● 63) October 2004
cGMP mediated signaling in smooth muscle Department of
Pharmacology, University of Münster, Germany
● 64) Nov. 2004
cGMP mediated signaling in smooth muscle, Division for Cardiavascular
Disease, Albany Medical College, Albany, NY
● 65) Dec. 2004
Can we live without cGMP? NO of course!, Department for Biochemistry
and Biophysics, University of Sherbrooke, Quebec, Canada
● 66) March 2005
NO more cGMP, Department of Biochemistry & Molecular Biology,
Medical College Georgia, Augusta, Georgia
● 67) March 2005
NO more cGMP, Department of Pathology/UVM Lung Center, University
of Vermont, Burlington, VT
17
Dostmann
CV
● 68) April 2005
HMR1766 specifically activates the oxidized form of the NO-sensitive
guanylyl cyclase, DG Cardiovascular Disease, Aventis Pharma, Frankfurt, Germany
● 69) April 2005
Smooth Muscle: Just say NO to cGMP, Department of Biochemistry,
University of Frankfurt, Germany
● 70) May 2005
cGMP: To boldly go where NO has gone before, Department of
Pharmacology, Columbia University, NY
● 71) August 2005
Exploring Vasomotor Mechanisms using new PKG inhibitors, Scios Inc.,
Freemont, California
● 72) August 2005
Cygnets - spatial and temporal dynamics of intracellular cGMP, Scios Inc.,
Freemont, California
● 73) Sept. 2005
Smooth Muscle: Just say NO to cGMP, Department of Pharmacology,
Vanderbilt University, Nashville, TN
● 74) Nov. 2005
NO more cGMP, Department of Medicine (Endocrinology), University of
Chicago, Chicago, IL
● 75) Dec. 2005
Intracellular Signaling of cGMP and cGMP-dependent Protein Kinase in
Smooth Muscle, BayerHealthcare, Wuppertal, Germany
● 76) Dec. 2005
Can we live without cGMP? NO of course!, University of Kassel, Germany
● 77) April 2006
Toxins in our Homes, Community Medical College, University of
● 78) May 2006
Don’t FRET the small stuff: cGMP in vascular smooth muscle, Monash
University, Melbourne, Australia
● 79) May 2006
Intracellular Signaling of cGMP and cGMP-dependent Protein Kinase in
Smooth Muscle, Royal Melbourne Institute of Technology, School of Medical Sciences,
Bundoora, Australia
● 80) March 2007
Novel activators of cGMP-dependent protein kinase, BayerHealthcare,
Wuppertal, Germany
● 81) Nov. 2007
Differential patterning of cGMP in vascular smooth muscle, Harvard
Medical School, Cardiovascular Research Center, MGH, Boston, MA
● 82) Dec. 2007
Differential patterning of cGMP in vascular smooth muscle, University of
California at San Diego, Department of Chemistry and Biochemistry and the Department of
Pharmacology, San Diego, CA
● 83) February 2008 cGMP, to boldly go where NO has gone before, Albany College of
Pharmacy, Albany, NY
● 84) March 2008
Rochester, Aab Cardiovascular Research Institute, School of Medicine and Dentistry, Rochester
NY
● 85) April 2008
Tennessee at Memphis, Department of Physiology, Memphis, TN
● 86) June 2008
cGMP, to boldly go where NO has gone before, Neuroscience Summer
Research Program, Department of Neurology, University of Vermont, College of Medicine,
Burlington, VT
● 87) July 2008
The dynamics and differential patterning of intracellular cGMP,
University of Gent, Department for Molecular Biomedical Research, Gent, Belgium
● 88) July 2008
The dynamics and differential patterning of intracellular cGMP,
18
Dostmann
CV
University College London, Wolfson Institute for Biomedical Research, London, UK
● 89) January 2009
Novel cGMP-Biosensors, Lonza AG, Cologne, Germany
● 90) Sept. 2009
cGMP-biosensors, Pfizer, Groton, CT
● 91) April 2010
The crystal structure of cGMP-dependent protein kinase,
BayerHealthcare, Wuppertal, Germany
XIV. Conferences, Workshops and (selected) Proceedings
● 1) February 1987 FAB-induced Reactions of cyclic Nucleotide Analogs in the Matrix, 20.
Diskussionstagung Massenspektrometrie, Oldenburg, Germany
● 2) June 1988Characterisation of the Arg331Lys mutant form of the regulatory subunit of
cAMP-dependent kinase typ I, Gordon Research Conference, Second Messengers & Protein
Phosphorylation, Kimball Union Academy, Meriden, NH, USA
● 3) July 1988 cAMP-dependent protein kinase - A framework for a diverse family of enzymes,
Cold Spring Harbor Symposium on Quantitative Biology, Cold Spring Harbor, NY
● 4) February 1989 Site-Directed Mutagenesis of the Regulatory Subunit of cAMP-Dependent
Protein Kinase: Characterisation of cAMP binding site B, UCLA Symposium on Molecular Biology
and Cellular Biology, J. Cell. Biochem.18, 66
● 5) June 1989Characterisation of the cAMP binding site B of the regulatory subunit of cAMPDependent Protein Kinase using site-directed mutagenesis, Gordon Research Conference,
Enzymes, Coenzymes and Metabolic Pathways, Kimball Union Academy, Meriden, New
Hampshire, USA
● 6) July 1989 Mutations affecting the interaction between cAMP and binding domain B of the
regulatory subunit of cAMP-dependent kinase, J. Cell Biol., 107, 490
● 7) February 1990 cAMP-dependent protein kinase: structural features of an enzyme family,
AAAS Annual Meeting, New Orleans, LA
● 8) May 1990 The Role of MgATP in Dissociation of cAMP-dependent Protein Kinase I, 2nd
Nordic Conference on Protein Engineering, Helsingør, Denmark
● 9) June 1990Alignment and modeling of cAMP binding sites in cAMP dependent protein
kinases, (1990), Adv. Second Messenger Phosphoprotein Res. 24, 725
● 10) June 1990A rational approach to design antagonists of cyclic AMP, cyclic GMP and 1,4,5IP3, (1990), Adv. Second Messenger Phosphoprotein Res. 24, 533
● 11) June 1990Comparison of the two classes of binding sites A and B of type I and type II cAMPdependent protein kinases by using phosphorothioate analogs of cAMP, (1990), Adv. Second
Messenger Phosphoprotein Res. 24, 231
● 12) July 1990 Probing the role of Mg/ATP in dissociation of cAMP-dependent protein kinase I
with cyclic adenosine-3',5'-phosphorothioates and mutant forms of the regulatory subunit,
ASBM/AAi Joint Meeting, FASEB J., 4, A2073
● 13) July 1990 cAMP-dependent protein kinase, FASEB J., 4, A2167
● 14) Sept. 1990
cAMP-dependent Protein Kinase: Probing the cAMP-binding sites with
derivatives of cAMP, 4th Symposium on Protein Kinases, Geilo, Norway
● 15) October 1991
Predicted Structure of the catalytic domain of the cGMP-dependent
protein kinase, 5th Symposium on Protein Kinases, Geilo, Norway
● 16) October 1992
Cloning and expression of the catalytic and regulatory domain of cGMPdependent protein kinase, 6th Symposium on Protein Kinases, Ullensvang, Norway
19
Dostmann
CV
● 17) March 1993
Klonierung und bakterielle Expression der katalytischen und
regulatorischen Untereinheit der cGMP-abhängigen Proteinkinase. 34. Frühjahrstagung der
Deutschen Gesellschaft für Pharmakologie und Toxikologie, Mainz, Germany, NaunynSchmiedeberg's Arch. Pharmacol. 347, 66
● 18) May 1993
Biochemical properties of a monomeric regulatory subunit of cAMPdependent protein kinase, FASEB J., 7, A1122
● 19) May 1994
Determination of the specificities of cAMP- and cGMP-dependent protein
kinases with peptide libraries on cellulose paper, in: Peptides 1994 (Maia, H.L.S. ed.), ESCOM,
Leiden, 481-482
● 20) Sept. 1994
The structures of cyclic nucleotide-dependent protein kinases. 8th
Symposium on Protein Kinases. Geilo, Norway
● 21) March 1995
Mutation zur Aufklärung der kooperativen Aktivierung der cAMPabhängigen Proteinkinase, 36. Frühjahrstagung der Deutschen Gesellschaft für Pharmakologie
und Toxikologie, Mainz, Germany, Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 73
● 22) March 1995
A chimeric mutant of cAMP- and cGMP-dependent protein kinase
regulatory subunits, 36. Frühjahrstagung der Deutschen Gesellschaft für Pharmakologie und
Toxikologie, Mainz, Germany Naunyn-Schmiedeberg's Arch. Pharmacol. 351, 74
● 23) Sept. 1995
Expression of a chimeric, cGMP sensitive regulatory subunit of cAMPdependent protein kinase I, 20th European Symposium, Hormones and Cell Regulation, Mt.
Sainte-Odile, France
● 24) Sept. 1996
cGMP-binding site mutations define the biochemical properties of the
cGMP-kinase I, Herbsttagung der Gesellschaft für Biochemie und Molecularbiologie, Leipzig,
Germany, Biol. Chem. 377, 148
● 25) Sept. 1996
Synthetic peptide libraries: Tools in the sytematic analysis of enzyme
substrate recognition, Herbsttagung der Gesellschaft für Biochemie und Molecularbiologie,
Germany, Biol. Chem. 377, 93
● 26) March 1997
Systematic development of specific cGMP-dependent protein kinase
peptides with combinatorial libraries. 38. Frühjahrstagung der Deutschen Gesellschaft für
Pharmakologie und Toxikologie, Mainz, Germany, Naunyn-Schmiedeberg's Arch. Pharmacol.,
355, 231
● 27) March 1997
Systematic development of specific cGMP-dependent protein kinase
peptides with combinatorial libraries. 38. Frühjahrstagung der Deutschen Gesellschaft für
Pharmakologie und Toxikologie, Mainz, Germany, Naunyn-Schmiedeberg's Arch. Pharmacol.,
355, 231
● 28) May 1997
Identification of specific cGMP-dependent protein kinase substrate and
inhibitor peptides with combinatorial libraries, Herbsttagung der Gesellschaft für Biochemie und
Molecularbiologie, Tuebingen, Biol. Chem. 378, 68
● 29) May 1997
Identification of amino acid residues which define the pathway of
cooperative activation of cGMP-kinase I, Herbsttagung der Gesellschaft für Biochemie und
Molecularbiologie, Tuebingen, Biol. Chem. 378, 155
● 30) Sept. 1997
Determination of specific cGMP-dependent protein kinase substrate and
inhibitor peptides with combinatorial libraries. International Symposium on Protein
Phosphorylation, Stockholm, Sweden
20
Dostmann
CV
● 31) June 1998
Specific substrate and inhibitor peptides of cGMP-dependent kinase I, 11th
Protein Kinase Symposium: Cyclic-Nucleotide-Dependent Signaling Mechanisms, Bergen,
Norway
● 32) Sept. 1998
Identification of highly specific cGMP-dependent protein kinase I
inhibitor peptides utilizing predisposed peptide libraries, 1st Internatl. Conference on Inhibitors
of Protein Kinases, Warsaw, Poland
● 33) Nov. 1998
Structure/Function of cyclic-nucleotide dependent protein kinases,
1st Conference on Kinomics: Dynamic Molecular Dynamics in Life Sciences, Landshut, Germany
● 34) March 1999
cGMP-dependent protein kinase in intracellular signaling, 15th Regional
Cancer research Symposium: Targeted Therapeutics in Cancer, Burlington, VT
● 35) May 1999
Protein Interactions: FRET and Surface Plasmon Resonance, Vermont
Cancer Center, Cell Signaling and Growth Control, Bishop Conference Center, Burlington, VT
● 36) July 1999
cGMP-dependent protein kinase in intracellular signaling, Analysis of
Biomolecular Interactions, Surface-Plasmon-Resonance-Biosensor Workshop, BioTul
Instruments Munich, Germany
● 37) October 1999
Highly specific cGMP-dependent protein kinase inhibitors from
combinatorial libraries with translocation properties across the plasma membrane, 7th New
England Smooth Muscle Meeting, October 15-16th, Boston University Medical Center, Boston,
MA
● 38) Nov. 1999
Selective cGMP-dependent protein kinase inhibitor peptides University of
Vermont, Department of Pharmacology, 1st Annual Research Retreat, Stowe, VT
● 39) Feb. 2000
Design of fluorescent indicators for cGMP. 44th Annual Biophysical Society
Meeting, New Orleans, LA, Biophysical J. 78, 884
● 40) March 2000
Inhibition of PKA and PKG by PPI peptide mimics. Annual Meeting of the
American Chemical Society, San Francisco, CA
● 41) August 2000
Highly specific and cell-penetrating cGMP-dependent protein kinase Ia
inhibitors from peptide libraries, 12th Protein Kinase Symposium: (NO / cGMP) Bad Brückenau,
Germany
● 42) August 2000
Design of fluorescent in vivo indicators for cGMP, 12th Protein Kinase
Symposium: (NO / cGMP) Bad Brückenau, Germany
● 43) Nov. 2000
New fluorescent cGMP-indicators. University of Vermont, Department of
Pharmacology, 2nd Annual Research Retreat, Stowe, VT
● 44) March 2001
Crystallization of cGMP-dependent protein kinase I alpha isoform.
DOE-EPSCoR Symposium, University of Vermont, Structural Biology Cluster, VT
● 45 )May 2001
Development of highly specific, membrane permeable peptide blockers of
cGMP-dependent protein kinase utilizing affinity selection from peptide libraries. Proceedings of
the Second International and the Seventeenth American Peptide Symposium, San Diego, CA,
191-193
● 46) April 2001
fluorescent indicator, 11th International Conference on Second Messengers and
Phosphoproteins, Melbourne, Australia
● 47) April 2001
Highly specific, membrane permeant peptide blockers of cGMPdependent protein kinase I, 11th International Conference on Second Messengers and
Phosphoproteins, Melbourne, Australia
21
Dostmann
CV
● 48) July 2001
The potential role of cGMP indicators in the human vasculature
4th Annual Totman Medical Trust Research Symposium, University of Vermont, Burlington, VT
● 49) Sept. 2001
Highly Specific and Membrane Permeant Peptide Inhibitors of cGMPdependent Protein Kinase Ia, 2nd International Conference onInhibitors of Protein Kinases,
Warsaw, Poland
● 50) Nov. 2001
fluorescent indicator, 9th Northeast Smooth Muscle Society Meeting, Boston Biomedical
Research Institute (BBRI), Watertown, Massachusetts
● 51) Nov. 2001
cGMP and cGMP-dependent protein kinase in intracellular signaling.
University of Vermont, Department of Pharmacology, 3rd Annual Research Retreat, Stowe,
Vermont
● 52) January 2002
Exploring vasomotor mechanisms using highly selective inhibitors of
cGMP-dependent protein kinase. National Cardiovascular Center COE, International Symposium
on Endogenous Vasodilators, Osaka, Japan
● 53) January 2002
Spatiotemporal dynamics of guanosine 3',5'-cyclic monophosphate
revealed by a genetically encoded, fluorescent indicator. National Cardiovascular Center COE,
International Symposium on Endogenous Vasodilators, Osaka, Japan
● 54) Feb. 2002
cGMP signaling in smooth muscle cells examined by FRET-based
indicators. Annual Biophysical Society Meeting, Boston, MA, Biophys. J. 82, 273a
● 55) June 2002
Cygnets: the dynamics of intracellular cGMP revealed by genetically
encoded fluorescent indicators. Gordon Research Conference on Cyclic Nucleotide
Phosphodiesterases, Mt. Holyoke College, MA
● 56) July 2002
Cygnets: spatial and temporal analysis of intracellular cGMP in human
vascular smooth muscle cells. 5th Annual Totman Medical Trust Research Symposium,
University of Vermont, Burlington, VT
● 57) Sept. 2002
Cygnets: the dynamics of intracellular cGMP revealed by genetically
encoded fluorescent indicators. 13th Protein Kinase Symposium, Oslo, Norway
● 58) Sept. 2002
Probing non-covalent protein-ligand interactions of cGMP-dependent
protein kinase by nanoflow ESI orthogonal time of flight mass spectrometry, 13th Protein Kinase
Symposium, Oslo, Norway
● 59) Sept. 2002
Specific inhibition of PKG reverses cGMP-dependent phenotypic
modulation in vascular smooth muscle cells, 10th Northeast Smooth Muscle Society Meeting,
Burlington, VT
● 60) Sept. 2002
protein kinase by nanoflow ESI orthogonal time of flight mass spectrometry, 10th Northeast
Smooth Muscle Society Meeting, Burlington, VT
● 61) Sept. 2002
Uptake characteristics of the PKG inhibitor DT-2 in smooth muscle cells,
th
10 Northeast Smooth Muscle Society Meeting, Burlington, VT
● 62) Sept. 2002
cGMP signaling in smooth muscle revealed by FRET-based indicators, 10th
Northeast Smooth Muscle Society Meeting, Burlington, VT
● 63) January 2003
cGMP transients in smooth muscle cells examined and quantified by FRETbased indicators, New England Pharmacologists 32nd Annual Meeting, Burlington, VT
● 64) February 2003 Cygnets: spatial and temporal analysis of intracellular cGMP, 23rd
Western Pharmacology Society Annual Meeting, South Lake Tahoe, Nevada
22
Dostmann
CV
● 65) June 2003
Delivery of Small DNA Fragments to Human Airway Epithelial Cells via
Arginine-rich Polypeptides. American Society for Gene Therapy, Washington DC
● 66) August 2003
Locating substrate and inhibitory binding sites on the cGMP-dependent
protein kinase unsing photyoaffinity labeling and mass spectrometry, 51 Annual Meeting of the
American Society of Mass Spectrometry, Montreal, Canada
● 67) August 2003
protein kinase by nanoflow ESI orthogonal time of flight mass spectrometry, 51 Annual Meeting
of the American Society of Mass Spectrometry, Montreal, Canada
● 68) June 2003
The spatial and temporal dynamics of intracellular cGMP in smooth
muscle, 1st International Conference on NO and cGMP, Leipzig, Germany
● 69) June 2003
Cygnets: in vitro characterization of novel cGMP indicators and in vivo
imaging of intracellular cGMP, 1st International Conference on NO and cGMP, Leipzig, Germany
● 70) June 2003
Cellular uptake mechanisms of membrane translocating cGMP-dependent
protein kinase peptide inhibitors, 1st International Conference on NO and cGMP, Leipzig,
Germany
● 71) July 2003
The spatial and temporal dynamics of intracellular cGMP in smooth
muscle, FASEB Research Conferences , Smooth Muscle, Snowmass Village, Colorado
● 72) July 2003
cGMP in smooth muscle, 6th Annual Totman Medical Trust Research
Symposium, University of Vermont, Burlington, VT
● 73) October 2003
Intracellular cGMP signaling in smooth muscle, 11th Northeast
Smooth Muscle Society Meeting, October 19, Providence, Rhode Island
● 74) April 2004
cGMP-dependent Protein Kinase. Cyclic Nucleotide Binding Site
Workshop, University of California at San Diego, La Jolla
● 75) July 2007
cGMP biosensors in smooth muscle, 7th Annual Totman Medical Trust
Research Symposium University of Vermont, Burlington
● 76) Sept. 2004
Monitoring intracellular cGMP. 14th Protein Kinase Symposium, Oslo,
Norway
● 77) Sept. 2004
Modulation od soluble guanylyl cyclase and cGMP dynamics in primary
smooth muscle cells. 14th Protein Kinase Symposium, Oslo, Norway
● 78) Sept. 2004
Membrane-permeable cygnets: rapid cellular internalization of
fluorescent cGMP-indicators. 14th Protein Kinase Symposium, Oslo, Norway
● 79) Sept. 2004
Specific and membrane permeable inhibitors of cGMP-dependent protein
kinase 3rd International and 28th European Peptide Symposium, Prague, Czech Republic
● 80) October 2004
PKG expression in smooth muscle 12th Annual Meeting North East
Smooth Muscle Society Meeting, University of Massachusetts Medical School, Worcester, MA
● 81) June 2005
The PKG inhibitor DT-2 reveals a novel mechanism of vasoregulation in
smooth muscle, 2st International Conference on NO and cGMP, Potsdam, Germany
● 82) June 2005
The temporal dynamics of intracellulat cGMP in vascular smooth muscle
st
cells, 2 International Conference on NO and cGMP, Potsdam, Germany
● 83) July 2005
Vasomotror mechanisms in vascular smooth muscle, 8th Annual Totman
Medical Trust Research Symposium, University of Vermont, Burlington
● 84) July 2006
The dynamics of intracellular cGMP in smooth muscle, FASEB Research
Conferences , Smooth Muscle, Snowmass Village, Colorado
23
Dostmann
CV
● 85) July 2006
Binding site mutations reveal a novel mechanism of the activation of
cGMP-dependent protein kinase, FASEB Research Conferences , Smooth Muscle, Snowmass
Village, Colorado
● 86) July 2006
Specific inhibitors help to elucidate the role of PKG in the control of
vasomotor mechanisms, FASEB Research Conferences , Smooth Muscle, Snowmass Village,
Colorado
● 87) July 2006
The spatial and temporal dynamics of intracellular cGMP in vascular
th
smooth muscle, 9 Annual Totman Medical Trust Research Symposium, University of Vermont,
Burlington, VT
● 88) Sept. 2006
FEBS/EMBO Workshop, 15th Protein Kinase Meeting - 'Spatial and
Temporal Regulation of Signalling' Oslo, Norway
● 89) June 2007
FlincGs: novel, non-FRET cGMP biosensors with nanomolar sensitivity for
NO-induced signaling 3rd International Conference on NO and cGMP, Dresden, Germany
(presented by Lydia Nausch)
● 90) August 2007
Novel cGMP-Biosensors, 13th International Conference on Second
Messengers and Phosphoproteins, San Diego, CA
● 91) July 2008
Novel Biosensors for Second Messengers, 11th Annual Totman Medical
Trust Research Symposium, University of Vermont, Burlington, VT
● 92) Sept. 2008
The spatial and temporal dynamics of intracellular cGMP in vascular
smooth muscle. 16th Protein Kinase Symposium and FEBS workshop on Cell Signaling Systems,
Oslo, Norway
● 93) Sept. 2008
Differential patterning of intracellular cGMP. 16th Protein Kinase
Symposium and FEBS workshop on Cell Signaling Systems, Oslo, Norway
● 94) June 2009
The role of basal PKG in the control of vasomotor reactivity,
4th Internatl. Conference on Inhibitors of Protein Kinases, Warsaw, Poland
XV. Peer-Reviewed Publications
● 1)
Dostmann W, Kleemeyer H and Engelhard G Stereochemical analysis of an unknown
metal organic compound by MS-, IR-, and NMR-spectroscopy, Bremer Brief Chem, 2: 48-56,
(1978)
● 2)
Genieser HG, Dostmann W, Bottin U, Butt E and Jastorff B Synthesis of nucleoside-3',5'cyclic phosphorothioates by cyclothiophosphorylation of unprotected nucleosides, Tetrahedron
Lett, 29: 2803-2804, (1988)
● 3)
Taylor SS, Buechler JA, Slice LW, Knighton DK, Durgerian S, Ringheim GE, Neitzel JJ,
Yonemoto W, Sowadski JM and Dostmann W, cAMP-dependent protein kinase - A framework
for a diverse family of enzymes, CSH Symp Quant Biol, 53: 121-130 (Review), (1988)
● 4)
Genieser HG, Butt E, Bottin U, Dostmann W and Jastorff B Synthesis of the 3',5' cyclic
phosphates from unprotected nucleosides, Synthesis, (1): 53-54, (1989)
● 5)
Meijer L, Dostmann W, Genieser HG, Butt E and Jastorff B, Starfish oocyte maturation:
evidence for a cyclic AMP-dependent inhibitory pathway, Dev Biol, 133: 58-66, (1989)
● 6)
Dostmann W, Genieser HG, Bottin U and Jastorff B Verfahren zur Herstellung von EnzymAgonisten und Antagonisten, Ger. Pat. DE 38 02 865 A1; Chem Abstr. 112, P56587, (1990)
● 7)
Genieser HG, Dostmann W, Bottin U and Jastorff B Verfahren zur Herstellung von EnzymAgonisten, Ger. Pat. DE 38 02 866 A1; Chem Abstr. 112, P 56588, (1990)
24
Dostmann
CV
● 8)
Dostmann WRG, Taylor SS, Genieser HG, Jastorff B, Døskeland S and Øgreid D Probing the
cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of
adenosine cyclic-3',5' phosphorothioates, (1990), J Biol Chem, 265: 10484-10491
● 9)
Neitzel JJ, Dostmann WRG and Taylor SS Role of MgATP in the activation and
reassociation of cAMP-dependent protein kinase I: Consequences of replacing the essential
arginine in cAMP-binding site A, Biochemistry, 30: 733-739, (1991)
● 10) Leon DA, Dostmann WRG. and Taylor SS Unfolding of the regulatory subunit of cAMPdependent protein kinase I, Biochemistry, 30: 3035-3040, (1991)
● 11) Dostmann WRG and Taylor SS Identifying the molecular switches that determine whether
(Rp)-cAMPS functions as an antagonist or an agonist in the activation of cAMP-dependent
protein kinase, Biochemistry, 30: 8710-8716, (1991)
● 12) Hofmann F, Dostmann W, Keilbach A, Landgraf W and Ruth P Structure and
physiological role of cGMP-dependent protein kinase, Biochim Biophys Acta, 1135: 51-60
(Review), (1992)
● 13) Schaap P, van Ments-Cohen M, Soede RDM, Brandt R, Firtel RA, Dostmann W, Genieser
HG, Jastorff B and van Haastert PJM Cell-permeable non-hydrolysable cAMP derivatives as tools
for analysis of signaling pathways controlling gene regulation in Dictyostelium, J Biol Chem,
268: 6323-6331, (1993)
● 14) Su Y, Taylor SS, Dostmann WRG, Xuong NH, and Varughese KI Crystallisation of a deletion
mutant of the R-subunit of cAMP-dependent protein kinase, J Mol Biol, 230: 1091-1093, (1993)
● 15) Øgreid D, Dostmann WRG, Genieser HG, Niemann P, Døskeland SO and Jastorff B. 8Piperidino-cAMPS (Rp/Sp) discriminate uniquely between site A and B of the regulatory subunits
of cAMP-dependent protein kinase type I and II, Eur J Biochem, 221: 1089-1094, (1994)
● 16) Herberg FW, Dostmann WRG, Zorn M, Davis SJ and Taylor SS Crosstalk between domains
in the regulatory subunit of cAMP-dependent protein kinase: influence of amino-terminus on
cAMP-binding and holoenzyme formation, Biochemistry 33: 7485-7494, (1994)
● 17) Zorn M, Fladmark K, Øgreid D, Jastorff B, Døskeland SO and Dostmann WRG Alanin 335 is
essential for high-affinity cAMP-binding of both sites A and B of cAMP-dependent protein kinase
type I, FEBS Lett, 362: 291-29, (1995)
● 18) Su Y, Dostmann WRG, Herberg FW, Durick K, Xuong NH, Ten Eyck L, Taylor SS and
Varughese KI Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP
binding domains, Science, 269: 807-813, (1995)
● 19) Tegge W, Frank R, Hofmann F and Dostmann WRG Determination of cyclic nucleotidedependent protein kinase substrate specificity by the use of peptide libraries on cellulose paper,
Biochemistry, 34: 10569-10577, (1995)
● 20) Wild N, Herberg FW, Hofmann F and Dostmann WRG Expression of a chimeric, cGMPsensitive regulatory subunit of cAMP-dependent protein kinase I, FEBS Lett 374: 356-362, (1995)
● 21) Dostmann WRG (Rp)-cAMPS inhibits the cAMP-dependent Protein Kinase by blocking the
cAMP-induced conformational transition, FEBS Lett, 375: 231-234, (1995)
● 22) Tegge W, Dostmann W, Hofmann F and Frank R Determination of the specificities of
cAMP- and cGMP-dependent protein kinases with peptide libraries on cellulose paper, Peptides
(Maia, H.L.S. ed.), ESCOM, Leiden, 481-482 (Review), (1995)
25
Dostmann
CV
● 23) Herberg FW, Taylor SS and Dostmann WRG Active site mutations define the pathway for
the cooperative activation of cAMP-dependent protein kinase, Biochemistry, 35: 2934-2942,
(1996)
● 24) Huq I, Dostmann WRG and Øgreid D Ile368 is involved in low-affinity binding of N6modified cAMP analogs to site B of the regulatory subunit of cAMP-dependent protein kinase I,
Biochem J, 316: 337-343, (1996)
● 25) Dostmann WRG, Koep N and Endres R The catalytic domain of the cGMP-dependent
protein kinase I influences the kinetic characteristics of the cGMP-binding sites, FEBS Lett, 398:
206-210, (1996)
● 26) Ruth P, Pfeifer A, Kamm S, Klatt P, Dostmann WRG and Hofmann F, Identification of the
amino acid sequences responsible for high affinity activation of cGMP kinase I, J Biol Chem, 272:
10522-10528, (1997)
● 27) Dostmann, WRG, Nickl, C, Frank, R and Tegge, W Identification of highly specific
cGMP-dependent protein kinase I inhibitor peptides utilizing predisposed peptide libraries, Cell
Mol Biol Lett 3: 287-289, (1998)
● 28) Pfeifer A, Ruth P, Dostmann WRG, Klatt P and Hofmann F Structure and function of cGMPdependent protein kinase, Rev Physiol Biochem Pharmacol, 135: 105-149, (Review), (1999)
● 29) Dostmann WRG, Nickl C, Thiel S, Tsigelny I, Frank R and Tegge W, Development of specific
substrate and inhibitor peptides of the cGMP-dependent protein kinase type I by cellulose paper
based combinatorial libraries, Pharm & Ther, 82: 373-387, (1999)
● 30) Dostmann WRG, Nickl CK, Taylor MS, Brayden JE, Frank R and Tegge WJ Highly specific,
membrane permeant peptide blockers of cGMP-dependent protein kinase Iα inhibit NO-induced
cerebral dilation, Proc Natl Acad Sci USA, 97: 14772-14777, (2000)
● 31) Honda A, Adams SR Sawyer CL, Lev-Ram V, Tsien RY and Dostmann WRG Spatiotemporal
dynamics of guanosine 3’,5’-cyclic monophosphate revealed by a
genetically encoded, fluorescent indicator, Proc Natl Acad Sci USA, 98: 2437-2442, (2001)
● 32) Dostmann, WRG, Nickl, CK, Taylor MS, Brayden JE, Frank R and Tegge, WJ New
peptide inhibitors of cGMP-dependent protein kinase type Iα, Cell Biol Mol Lett, 6: 458-460,
(2001)
● 33) Tegge W, Frank R, Taylor MS, Brayden JE, Nickl C, Dostmann WRG Development of highly
specific, membrane permeable peptide blockers of cGMP-dependent protein kinase utilizing
affinity selection from peptide libraries. Peptides: The Wave of the Future, (Eds, M. Lebel, RA
Houghten), Academic Press, San Diego, p191-193 (Review), (2001)
● 34) Dostmann WRG, Nickl, CK, Taylor MS, Brayden JE, Frank R and Tegge WJ A new class of
cGMP-dependent protein kinase peptide inhibitors and their role in elucidating vasomotor
mechanisms, Pharm & Ther, 93: 203-215, (2002)
● 35) Sawyer CL, Honda A and Dostmann WRG. Cygnets: spatial and temporal analysis of
intracellular cGMP, Proc Western Pharmacol Soc, 46: 28-31, (2003)
● 36) Dostmann WRG. Inhibitors of cyclic nucleotide dependent protein kinases,Handbook of
Cell Signal. Academic Press (Eds. Bradshaw & Dennis), 201: 487-493 (Review), (2003)
● 37) Taylor, MS, Okwuchukwuasanya, C, Nickl, CK, Brayden, JE and Dostmann, WRG, Unique
inhibitory properties of the cell-permeable cGMP-dependent protein kinase inhibitor DT-2 reveal
a novel mechanism of vasoregulation, Mol Pharm, 65: 1111-1119, (2004)
26
Dostmann
CV
● 38) Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda
T, Aufiero K, Zaccolo M, Dostmann WRG, Smith CJ, Kass DA. cGMP Catabolism by PDE5
Regulates Cardiac Adrenergic Stimulation by NOS3-Dependent Mechanism Circ Res 96: 100-9,
(2005)
● 39) Krieg T, Philipp S, Cui L, Dostmann WR, Downey JM, Cohen MV. Peptide blockers of PKG
inhibit ROS generation by acetylcholine and bradykinin in cardiomyocytes but fail to block
protection in the whole heart. Am J Physiol 288: H1976-81, (2005)
● 40) Zhu CB, Carneiro AM, Dostmann WR, Hewlett RA, and Blakely, RD, p38 MAPK Activation
Elevates Serotonin Transport Activity via a Trafficking-Independent, PP2A-Dependent Process, J
Biol Chem, 280: 15649-58, (2005)
● 41) Honda A, Moosmeier M, and Dostmann WR. Cygnets: Rapid cellular internalization of
fluorescent cGMP-indicators, Front Biosci, 10: 1290-1301, (2005)
● 42) Foley KF, De Frutos S, Laskovski KE, Tegge W and Dostmann WR. Culture conditions
influence uptake and intracellular localization of the membrane permeable cGMP-dependent
protein kinase peptide inhibitor DT-2, Front Biosci 10: 1302-1312, (2005)
● 43) Dey N, Foley KF, Lincoln TM and Dostmann WR. Inhibition of cGMP-dependent protein
kinase-I attenuates contractile protein expression and contractile morphology in cultured rat
aortic smooth muscle cells, J Cardiovasc Pharm, 45: 404-413, (2005)
● 44) Honda A, Sawyer CL, Cawley, SM and Dostmann WR. Cygnets: in vivo characterization of
novel cGMP indicators and in vivo imaging of intracellular cGMP, Methods Mol Biol 307: 27-44,
(2005)
● 45) Zhang R, Nickl CK, Mamai A, Flemer S, Natarajan A, Dostmann WR, Madalengoitia JS, PolyL-Proline Type II Peptide Mimics as Probes of the Active Site Occupancy Requirements of cGMP
Dependent Protein Kinase, J Peptide Res, 66: 151-159, (2005)
● 46) Hou Y, Wong E, Martin J, Schoenlein P, Dostmann WR and Browning DD, A Role for cyclicGMP dependent protein kinase in Anoikis, Cell Signal, 18: 882-888, (2006)
● 47) Sawyer CL, Honda A and Dostmann WR. Cygnets: intracellular cGMP-sensing in primary
cells using fluorescence indicators, Cell Biol, 2: 299-306, (2006)
● 48) Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T,
Kass DA, Paolocci N, Houslay MD, Zaccolo M, Compartmentalized phosphodiesterase-2 activity
blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway, Circ Res, 98: 226234, (2006)
● 49) Bove PF, Wesley UV, Greul AK, Hristova M, Dostmann WR, van der Vliet A. Nitric Oxide
Promotes Airway Epithelial Wound Repair through Enhanced Activation of MMP-9, Am J Respir
Cell Mol Biol. 36(2): 138-146, (2007)
● 50) Cawley SM, Sawyer CL, Brunelle KF, van der Vliet A, Dostmann WR. Nitric oxide-evoked
transient kinetics of cyclic GMP in vascular smooth muscle cells. Cell Signal, 19: 1023-1033,
(2007)
● 51) Scholten A, Fuss H, Heck AJ, Dostmann WR The hinge region operates as a stability
switch in cGMP dependent protein kinase I, FEBS J, 274:2274-2286, (2007)
● 52) Nausch L, Ledoux J, Bonev A, Nelson MT, Dostmann WR Differential patterning of cGMP in
vascular smooth muscle cells revealed by single GFP-linked biosensors, Proc Natl Acad Sci USA,
105: 365-370, (2008)
27
Dostmann
CV
● 53) Nickl, CK, Dostmann WRG. Selective inhibitors of cyclic nucleotide dependent protein
kinases, Handbook of Cell Signal. Academic Press, pp1479-1488, (Review), (2009)
● 54) Pinkse MW, Rijkers DT, Dostmann WR, Heck AJ, Mode of Action of cGMP-dependent Protein
Kinase-specific Inhibitors Probed by Photoaffinity Cross-linking Mass Spectrometry.
J Biol Chem. 284:16354-16368 (2009)
● 55) Steiner JA, Carneiro AM, Wright J, Matthies HJ, Prasad HC, Nicki CK, Dostmann WR,
Buchanan CC, Corbin JD, Francis SH, Blakely RD. cGMP-dependent protein kinase Ialpha
associates with the antidepressant-sensitive serotonin transporter and dictates rapid
modulation of serotonin uptake. Mol Brain. 5;2(1):26, (2009)
● 56) Nickl CK, Raidas SK, Zhao H, Sausbier M, Ruth P, Tegge W, Brayden JE, and Dostmann WR,
(D)-amino acid analogues of DT-2 as highly selective and superior inhibitors of cGMP-dependent
protein kinase Iα. Biochim Biophys Acta, 1804:524-32, (2010)
● 57) Lavogina D, Nickl CK, Enkvist E, Raidaru G, Lust M, Vaasa A, Uri A, Dostmann WR. Adenosine
analogue-oligo-arginine conjugates (ARCs) serve as high-affinity inhibitors and fluorescence
probes of type I cGMP-dependent protein kinase (PKGIalpha). Biochim Biophys Acta.
1804:1857-1868, (2010)
● 58) Batchelor AM, Bartus K, Reynell C, Constantinou S, Halvey EJ, Held KF, Dostmann WR,
Vernon J, Garthwaite J, Exquisite sensitivity to subsecond, picomolar nitric oxide transients
conferred on cells by guanylyl cyclase-coupled receptors, Proc Natl Acad Sci USA, in press,
(2010)
28

Dostmann CV 1 Curriculum Vitae Wolfgang R. Dostmann University

Transcription

Similar documents